RESEARCH MONOGRAPH · KDC-MN-098

Pterostilbene

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

64/100

Resveratrol's pharmacokinetically superior cousin. Better bioavailability, similar mechanism story, smaller human dataset

Pterostilbene is what you get when you methylate resveratrol's two meta hydroxyls. That tiny structural change does a lot for pharmacokinetics. Lipophilicity goes up, first-pass glucuronidation slows down, and oral bioavailability in rats is reported around 80% vs roughly 20% for resveratrol. Half-life is longer too. So if you actually wanted the resveratrol mechanism story to play out in vivo, pterostilbene is the better molecule to put through the test.

The blueberry literature is where this all started. Pterostilbene was identified as a major bioactive in blueberries and some grape varieties, the McCormick lab and others ran preclinical work on metabolic and oncology endpoints, and the human trial work has been thin but not terrible. The Riche 2014 pilot in hypercholesterolemic adults at 125mg/day twice daily showed modest LDL changes but also some BP changes that were not all in the direction you'd want. So even with better PK, the human signal is small.

Mechanism overlaps with resveratrol substantially: AMPK activation, NRF2 induction, putative SIRT activity though with the same caveats as resveratrol about the assay artifacts. Where pterostilbene plausibly differentiates is in the bioavailability-adjusted CNS exposure, which makes the cognitive aging work more interesting than the equivalent resveratrol experiments.

What we like: this is genuinely a more rational molecule than resveratrol for testing the polyphenol-AMPK-SIRT hypothesis. Better PK means the in vitro mechanistic story has at least a chance of being relevant at oral doses. Combination work with NMN or NR is where most of the interesting current research sits.

What we dont like is the marketing creep. Pterostilbene gets sold as a clear upgrade over resveratrol when the human RCT base is much smaller and many of the comparisons are extrapolated from rodent PK.

Sourcing is decent. Pterostilbene from reputable peptide and small-molecule suppliers runs 98%+ HPLC reliably, the molecule is stable, no special storage gymnastics required. Cost per gram is higher than resveratrol but not absurd.

Worth a slot in a polyphenol-aging research stack? yeah, more defensible than resveratrol on PK grounds alone. Just dont mistake better pharmacokinetics for proven efficacy.

Evidence: 52
Mechanism: 65
Reliability: 55
Safety: 82
Sourcing: 80
Value: 65
Signal: 55
Staying power: 58

Plain-language summary Intrigue 55 / 100

Pterostilbene is a methylated cousin of resveratrol with substantially better oral bioavailability. It is found in blueberries and is sold as a longevity and cognitive supplement, often combined with NAD+ precursors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Dimethylated resveratrol analog

A dimethylated resveratrol analog from blueberries with substantially improved oral bioavailability and similar SIRT1-related pharmacology.

Abstract

Pterostilbene (trans-3,5-dimethoxy-4'-hydroxystilbene; CAS 537-42-8; molecular formula C16H16O3; molecular weight 256.30) is a dimethoxy analog of resveratrol present at high concentrations in blueberries and Pterocarpus heartwood. The two methoxy groups (replacing two of the three hydroxyl groups in resveratrol) substantially increase lipophilicity and oral bioavailability while reducing first-pass conjugation. Plasma concentrations after oral administration are 4- to 10-fold higher than equivalent resveratrol exposures. Mechanism overlaps with resveratrol (SIRT1, AMPK, anti-inflammatory) but the higher achievable plasma exposure may produce more reliable clinical effects. Reported research dose ranges in the literature are typically 50 to 250 mg, lower than resveratrol on a milligram basis due to the bioavailability advantage. The compound is sold as a dietary supplement.

Mechanism of action

Dimethylated resveratrol with improved bioavailability; similar SIRT1/AMPK pharmacology.

Reported research dose ranges

50 to 250 mg (reported research dose ranges in the literature).

References

Kapetanovic IM, et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylated analog pterostilbene in rats. Cancer Chemother Pharmacol 2011.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-098

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Pterostilbene

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs